Table 4 Comparison of the pharmacokinetics (AUC, Cmax, half-life, and Tmax) of DS-7423 between US cohort and Japanese cohort
From: Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
Dose level | Study | Mean AUCtau [ng h/mL] | Mean Cmax [ng/mL] | T1/2 [h] | Tmax [h] |
|---|---|---|---|---|---|
4 | US cohort (n = 1) | 21.86 | 4 | 6–7 | 2–4 |
Japanese cohort (n = 3) | 31.1 | 3 | 6–7 | 2–4 | |
8 | US cohort (n = 1) | 131 | 20 | 6–7 | 2–4 |
Japanese cohort (n = 3) | 84.2 | 10 | 6–7 | 2–4 | |
16 | US cohort (n = 3) | 133.5 | 20 | 6–7 | 2–4 |
Japanese cohort (n = 2) | 178 | 18 | 6–7 | 2–4 | |
160 | US cohort (n = 4) | 1180.5 | 59 | 6–7 | 2–4 |
Japanese cohort (n = 3) | 1223.3 | 61 | 6–7 | 2–4 | |
240 | US cohort (n = 7) | 1458.2 | 92.0 | 12 | 2–4 |
Japanese cohort (n = 5) | 1184.8 | 83.6 | 12 | 2–4 |
